ONCO — Oncopeptides AB Share Price
Last trade - 00:00- SEK310.56m
- SEK321.72m
- SEK31.65m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.6 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -218.28% | ||
| Return on Equity | n/a | ||
| Operating Margin | -696.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | 118.3 | 8.36 | 35.22 | 31.65 | 89.45 | 185.4 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
Directors
- Per Woldolsen NEC (73)
- Marty Duvall CEO
- Annika Muskantor CFO (55)
- Eva Nordstrom COO (50)
- Klaas Bakker EVP (38)
- Jakob Lindberg CSO (48)
- Karolina Vilval GCN (41)
- Mohamed Ladha GMG (51)
- Andrea Passalacqua GMG (44)
- Rolf Gulliksen OTH (61)
- Fredrik Lehmann OTH (44)
- Karin Vanderpol OTH (47)
- Jonas Brambeck DRC (62)
- Per Samuelsson DRC (60)
- Jennifer Jackson IND (67)
- Jarl Jungnelius IND (71)
- Brian Stuglik IND (62)
- Cecilia Wennborg IND (57)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- September 5th, 2000
- Public Since
- February 22nd, 2017
- No. of Employees
- 75
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 211,263,903
- Address
- Luntmakargatan 46, 7th floor, STOCKHOLM, 111 37
- Web
- https://www.oncopeptides.se/
- Phone
- +46 86152040
- Contact
- David Augustsson
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Latest News for ONCO
Upcoming Events for ONCO
Oncopeptides AB Annual Shareholders Meeting
Q2 2025 Oncopeptides AB Earnings Release
Q3 2025 Oncopeptides AB Earnings Release
Similar to ONCO
2cureX AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 22:26 UTC, shares in Oncopeptides AB are trading at SEK2.00. This share price information is delayed by 15 minutes.
Shares in Oncopeptides AB last closed at SEK2.00 and the price had moved by -30.92% over the past 365 days. In terms of relative price strength the Oncopeptides AB share price has underperformed the FTSE Global All Cap Index by -34.33% over the past year.
The overall consensus recommendation for Oncopeptides AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOncopeptides AB does not currently pay a dividend.
Oncopeptides AB does not currently pay a dividend.
Oncopeptides AB does not currently pay a dividend.
To buy shares in Oncopeptides AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK2.00, shares in Oncopeptides AB had a market capitalisation of SEK422.53m.
Here are the trading details for Oncopeptides AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: ONCO
Based on an overall assessment of its quality, value and momentum Oncopeptides AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Oncopeptides AB is SEK4.70. That is 135% above the last closing price of SEK2.00.
Analysts covering Oncopeptides AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.97 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncopeptides AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +23.79%.
As of the last closing price of SEK2.00, shares in Oncopeptides AB were trading +10.06% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Oncopeptides AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK2.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Oncopeptides AB's management team is headed by:
- Per Woldolsen - NEC
- Marty Duvall - CEO
- Annika Muskantor - CFO
- Eva Nordstrom - COO
- Klaas Bakker - EVP
- Jakob Lindberg - CSO
- Karolina Vilval - GCN
- Mohamed Ladha - GMG
- Andrea Passalacqua - GMG
- Rolf Gulliksen - OTH
- Fredrik Lehmann - OTH
- Karin Vanderpol - OTH
- Jonas Brambeck - DRC
- Per Samuelsson - DRC
- Jennifer Jackson - IND
- Jarl Jungnelius - IND
- Brian Stuglik - IND
- Cecilia Wennborg - IND